Via Retrovirus Patents (Class 800/23)
-
Patent number: 8373018Abstract: A process for generating transgenic animals using recombinant lentiviruses. The process comprises injecting recombinant lentiviruses into the interstituim of the testis of a male to produce mature spermatozoa within a few days. The male with transgene expressing lentivirus is mated with a female, forming a progeny carrying the transgene.Type: GrantFiled: January 11, 2011Date of Patent: February 12, 2013Assignees: Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Department of BiotechnologyInventors: Sorab N. Dalal, Lalit Sehgal, Nileema Khapare, Rahul Thorat
-
Publication number: 20130024958Abstract: The present invention provides new lentiviral vectors that include an anti-repressor element (ARE) and, optionally, a scaffold attachment region (SAR). The lentiviral vectors provide expression of a heterologous nucleic acid in at least 50% of the cells of multiple cell types when used for lentiviral transgenesis. In certain embodiments of the invention the heterologous nucleic acid encodes an RNAi agent such as an shRNA. The invention further provides transgenic nonhuman animals generated using a lentiviral vector that includes an ARE and optional SAR. In addition, the invention provides a variety of methods for using the vectors including for achieving gene silencing in eukaryotic cells and transgenic animals, and methods of treating disease. The invention also provides animal models of human disease in which one or more genes is functionally silenced using a lentiviral vector of the invention.Type: ApplicationFiled: May 3, 2012Publication date: January 24, 2013Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Patrick Stern, Stephen Kissler
-
Publication number: 20120096573Abstract: A process for generating transgenic animals using recombinant lentiviruses. The process comprises injecting recombinant lentiviruses into the interstituim of the testis of a male to produce mature spermatozoa within a few days. The male with transgene expressing lentivirus is mated with a female, forming a progeny carrying the transgene.Type: ApplicationFiled: January 11, 2011Publication date: April 19, 2012Applicants: Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), DEPARTMENT OF BIOTECHNOLOGYInventors: Sorab N. Dalal, Lalit Sehgal, Nileema Khapare, Rahul Thorat
-
Patent number: 8134044Abstract: A transgenic animal such as a transgenic snake or other reptile that expresses a heterologous expression product is described, along with methods of making the same. In general, the animal comprises cells containing a sequence encoding the heterologous expression product. The sequence encoding the heterologous expression product is integrated into the genome of the animal (e.g., in some or all cells thereof, and in some embodiments into germ cells thereof). The sequence encoding the heterologous expression product is, in general, operatively associated with an expression sequence or promoter. The animals are useful for, among other things, testing of repellents, testing of toxicological compounds, as teaching aids, for venom production, etc.Type: GrantFiled: December 18, 2009Date of Patent: March 13, 2012Assignee: North Carolina State UniversityInventors: Paul E. Mozdziak, James N. Petitte
-
Patent number: 7993925Abstract: The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene. In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals (e.g., mice) expressing inducible (such as tetracycline-regulated), reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene.Type: GrantFiled: June 5, 2008Date of Patent: August 9, 2011Assignee: Cold Spring Harbor LaboratoryInventors: Ross Dickins, Scott W. Lowe, Gregory J. Hannon
-
Patent number: 7816578Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.Type: GrantFiled: September 30, 2005Date of Patent: October 19, 2010Assignees: Kyowa Hakko Kirin Co., Ltd., Medarex, Inc.Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
-
Patent number: 7718847Abstract: The present invention provides a method of producing a non-human vertebrate that harbours germ cells having a desired gene transferred thereto, comprising injecting the desired gene to the testis of a non-human vertebrate wherein no tight junction exists between Sertoli cells to transfer the desired gene to germ cells, so as to obtain a non-human vertebrate that harbours the germ cells having the desired gene transferred thereto. Using the method of the present invention, even in animal species and lines for which in vitro transduction has been difficult to date, it is possible to obtain an individual harbouring germ cells, particularly spermatogonial stem cells, having a desired gene transferred thereto, at extremely high efficiency.Type: GrantFiled: May 25, 2005Date of Patent: May 18, 2010Assignee: Kyoto UniversityInventors: Takashi Shinohara, Mito Shinohara
-
Patent number: 7663019Abstract: A transgenic animal such as a transgenic snake or other reptile that expresses a heterologous expression product is described, along with methods of making the same. In general, the animal comprises cells containing a sequence encoding the heterologous expression product. The sequence encoding the heterologous expression product is integrated into the genome of the animal (e.g., in some or all cells thereof, and in some embodiments into germ cells thereof). The sequence encoding the heterologous expression product is, in general, operatively associated with an expression sequence or promoter. The animals are useful for, among other things, testing of repellents, testing of toxicological compounds, as teaching aids, for venom production, etc.Type: GrantFiled: May 23, 2007Date of Patent: February 16, 2010Assignee: North Carolina State UniversityInventors: Paul E. Mozdziak, James N. Petitte
-
Patent number: 7521591Abstract: This invention provides eggs which contain exogenous proteins. The invention further provides transgenic chickens which express exogenous sequences in their oviducts, and vectors and methods for the stable introduction of exogenous nucleic acid sequences into the genome of a bird for expressing said exogenous sequences to alter the phenotype of the bird or to produce desired proteins.Type: GrantFiled: October 28, 2003Date of Patent: April 21, 2009Assignees: Synageva BioPharm Corp., University of Georgia Research FoundationInventors: Robert D. Ivarie, Alex J. Harvey, Julie A. Morris, Guodong Liu
-
Publication number: 20090064351Abstract: The present invention has its object to provide a transgenic bird producing erythropoietin at high concentration levels as well as a method for constructing the same. The present invention provides a G0 transgenic chimera bird as obtained by incubating a fertilized avian egg, infecting the early embryo formed after egg laying, except for the blastoderm stage immediately following egg laying, with a replication-deficient retroviral vector containing a foreign erythropoietin gene and allowing the embryo to hatch.Type: ApplicationFiled: February 24, 2006Publication date: March 5, 2009Applicant: Kaneka CorporationInventors: Shinji Iijima, Masamichi Kamihira, Kenichi Nishijima
-
Publication number: 20080178310Abstract: A transgenic non-human aquatic organisms, such as piscine, crustacean, mollusks, and the like, having a transgene which results in disrupting the production of and/or activity of growth differentiation factor-8 (GDF-8) chromosomally integrated into the germ cells of the aquatic organism is disclosed. Also disclosed are methods for making such organisms and nucleic acid sequences encoding GDF-8 polypeptides from such aquatic organisms.Type: ApplicationFiled: February 7, 2008Publication date: July 24, 2008Inventors: Se-Jin Lee, Alexandra C. McPherron
-
Publication number: 20080134352Abstract: The present invention relates to methods for producing transgenic animals, particularly transgenic rats, using retroviral constructs engineered to carry the transgene(s) of interest.Type: ApplicationFiled: January 28, 2008Publication date: June 5, 2008Applicant: California Institute of TechnologyInventors: David Baltimore, Elizabeth J. Hong, Carlos Lois-Caballe, Shirley Pease
-
Patent number: 7323619Abstract: The present invention relates to methods for producing transgenic animals, particularly transgenic birds and fish, using retroviral constructs engineered to carry the transgene(s) of interest.Type: GrantFiled: September 13, 2002Date of Patent: January 29, 2008Assignee: California Institute of TechnologyInventors: David Baltimore, Elizabeth J. Hong, Carlos Lois-Caballe, Shirley Pease
-
Patent number: 7294755Abstract: Disclosed is an in vivo method of incorporating exogenous genetic material into the genome of a vertebrate, which involves administering to a male vertebrate's testis a gene delivery mixture comprising a viral vector, such as a retroviral vector, to deliver a polynucleotide encoding a desired trait or product. Also disclosed is an in vitro method of incorporating exogenous genetic material into the genome of a vertebrate, in which germ cells are obtained from a donor male vertebrate and are genetically modified in vitro, before being transferred to a recipient male vertebrate. After the transfer, the male vertebrate bearing the genetically modified germ cells is bred with a female vertebrate such that a transgenic progeny is produced that carries the polynucleotide in its genome. Also disclosed are non-human transgenic vertebrates produced in accordance with the method, including transgenic progeny.Type: GrantFiled: May 12, 2000Date of Patent: November 13, 2007Assignees: Cedars-Sinai Medical Center, Imperial College Innovations Ltd.Inventors: Carol W. Readhead, Robert Winston
-
Patent number: 7282620Abstract: The present invention provides an experimental model animal which does not develop anaphylaxis, a type I allergy, can specifically induce Arthus reaction, a type III allergy, is not affected by type I allergy and evaluates type III allergy inflammation individually, and a method of screening a reaction accelerating or inhibitory substance in a type III allergy reaction through Fc?RIII by using said experimental model animal. In order to eliminate Fc?RIIB that demonstrates suppressive action to response through Fr?RIII, a mouse wherein the deletion mutation of both molecules of Lyn and Fc?RIIB are homozygotic (Lyn?IIB?) was generated by mating Lyn knockout mouse (Lyn?/?) and Fc?RIIB knockout mouse (Fc?RIIB?/?), and was used to measure and evaluate the deficiency of Fc?RIII function in systemic passive anaphylaxis and the reduction of Fc?RIII function in a bone marrow-derived mast cell, or the like.Type: GrantFiled: August 23, 2001Date of Patent: October 16, 2007Assignee: Japan Science and Technology AgencyInventors: Toshiyuki Takai, Masao Ono, Takae Yuasa, Takeshi Watanabe
-
Patent number: 7138562Abstract: The present invention provides improved methods and compositions for the generation of transgenic non-human animals. The present invention permits the introduction of exogenous nucleic acid sequences into the genome of unfertilized eggs (e.g., pre-maturation oocytes and pre-fertilization oocytes) by microinjection of infectious retrovirus into the perivitelline space of the egg. The methods of the present invention provide an increased efficiency of production of transgenic animals with a reduced rate of generating animals which are mosaic for the presence of the transgene.Type: GrantFiled: July 18, 2001Date of Patent: November 21, 2006Assignee: Wisconsin Alumni research FoundationInventors: Robert D. Bremel, Anthony W. S. Chan, Jane C. Burns
-
Patent number: 7041870Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.Type: GrantFiled: November 30, 2001Date of Patent: May 9, 2006Assignees: Medarex, Inc., Kirin Brewery Company LimitedInventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
-
Patent number: 6946266Abstract: The invention relates to a method of expressing proteins in higher eukaryotes in vitro. In general, the invention sets forth a method of expressing exogenous proteins as fusion partners with the immunoglobulin molecules of avian species specifically chickens. The technology involves, in one embodiment, retroviral-mediated gene transfer and transplantation of stem cells from the Bursa of Fabricus in chickens.Type: GrantFiled: December 18, 2001Date of Patent: September 20, 2005Assignee: Fred Hutchinson Cancer Research CenterInventor: Paul E. Neiman
-
Patent number: 6822137Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.Type: GrantFiled: February 4, 1999Date of Patent: November 23, 2004Assignees: Institut Pasteur, Universite Pierre et Marie CurieInventors: Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas
-
Patent number: 6734338Abstract: A composition for in vitro and in vivo transfection of vertebrate male germ cells comprises a nucleic acid or transgene, and a gene delivery system, and optionally a protective internalizing agent, such as an endosomal lytic agent, a virus or a viral component, which is internalized by cells along with the transgene and which enhances gene transfer through the cytoplasm to the nucleus of the male germ cell. A method of genetically altering a vertebrate male germ cell in vivo employs a lentiviral-derived vector. A method of substantially depopulating a vertebrate testis employs a combination of a dose of an alkylating agent, such as busulfan, chlorambucil, cyclophosphamide, melphalan, or ethyl ethanesulfonic acid, and a dose of gamma radiation. A pharmaceutical preparation and a transfer kit utilize the composition. A method for introducing a polynucleotide into vertebrate male germ cells comprises the administration of the composition to a vertebrate.Type: GrantFiled: May 13, 1999Date of Patent: May 11, 2004Assignees: Cedars-Sinai Medical Center, IMPEL, Imperial College of Science, Technology and MedicineInventors: Carol W. Readhead, Robert Winston
-
Patent number: 6730822Abstract: This invention provides vectors and methods for the stable introduction of exogenous nucleic acid sequences into the genome of a bird and for expressing said exogenous sequences to alter the phenotype of the bird or to produce desired proteins. In particular, transgenic chickens are produced which express exogenous sequences in their oviducts. Eggs which contain exogenous proteins are also produced.Type: GrantFiled: October 16, 1998Date of Patent: May 4, 2004Assignee: AviGenics, Inc.Inventors: Robert D. Ivarie, Alex J. Harvey, Julie A. Morris, Guodong Liu, Jeffrey C. Rapp
-
Publication number: 20030115622Abstract: A culture system for producing PGCs or EG cells by culturing PGCs for long periods in tissue culture is provided. This culture system uses LIF, bFGF, IGF and SCF. The resultant EG cells are useful for the production of transgenic and chimeric avians, in particular, chickens and turkeys, and also for cloning purposes.Type: ApplicationFiled: August 3, 1998Publication date: June 19, 2003Inventors: F. ABEL PONCE DE LEON, JAMES M. ROBL, STEVEN L. STICE, D. JOSEPH JERRY
-
Publication number: 20030074681Abstract: Vectors and methods are provided for introducing genetic material into cells of a chicken or other avian species. More particularly, vectors and methods are provided for transferring a transgene to an embryonic chicken cell, so as to create a transgenic hen wherein the transgene is expressed in the hen's oviduct and the transgene product is secreted in the hen's eggs and/or those of her offspring. In a preferred embodiment, the transgene product is secreted in the egg white.Type: ApplicationFiled: April 18, 1997Publication date: April 17, 2003Inventor: WILLIAM C. MACARTHUR
-
Patent number: 6548740Abstract: The present invention provides improved methods and compositions for the generation of transgenic non-human animals. The present invention permits the introduction of exogenous nucleic acid sequences into the genome of unfertilized eggs (e.g., pre-maturation oocytes and pre-fertilization oocytes) by microinjection of infectious retrovirus into the perivitelline space of the egg. The methods of the present invention provide an increased efficiency of production of transgenic animals with a reduced rate of generating animals which are mosaic for the presence of the transgene.Type: GrantFiled: February 11, 2000Date of Patent: April 15, 2003Assignee: Wisconsin Alumni Research FoundationInventors: Robert D. Bremel, Anthony W.S. Chan, Jane C. Burns
-
Publication number: 20030051260Abstract: The present invention pertains to a method for treating obesity in a mammal which comprises reducing the biological activity of HMGI genes in the mammal. In another embodiment, the invention pertains to a method for treating a tumor in a patient by reducing the biological activity of normal HMGI genes which comprises administering to the patient a therapeutically effective amount of an inhibitor compound active against normal HMGI-C or HMGI(Y) genes. In another embodiment, the invention pertains to a method of producing a transgenic non-human mammal, the germ cells and somatic cells of which contain an inactivated HMGI gene sequence introduced into the mammal at an embryonic stage. In another embodiment, the invention pertains to a method for screening candidate compounds capable of inhibiting the biological activity of normal HMGI proteins. In another embodiment, the invention pertains to a method for screening candidate compounds capable of inhibiting the biological activity of normal HMGI genes.Type: ApplicationFiled: January 6, 1999Publication date: March 13, 2003Inventors: KIRAN K. CHADA, HENA ASHAR, ALEX TKACHENKO, XIANJIN ZHOU
-
Patent number: 6512161Abstract: A transgenic rabbit which has in its genomic DNA sequences that encode apolipoprotein (a) and apolipoprotein B polypeptides which are capable of combining to produce lipoprotein (a), a process for creating such a rabbit, and the use of the rabbit to identify compounds which are effective in the treatment of human diseases which are associated with, induced and/or exacerbated by Lp(a) expression.Type: GrantFiled: January 8, 1999Date of Patent: January 28, 2003Assignee: Aventis Pharmaceuticals, Inc.Inventors: Didier Rouy, Nicolas Duverger, Florence Emmanuel, Patrice Denefle, Louis-Marie Houdebine, Celine Viglietta, Edward M. Rubin, Steven D. Hughes
-
Patent number: 6479285Abstract: The present invention involves the role of p53 in the differentiation of embryonic tissues. More particularly, the present invention provides methods of the blocking of p53 function in embryonic tissues, and the use of these tissues as screening tools for substances that are capable of overcoming the p53-related block in differentation, both in vitro and in vivo. The similarities between undifferentiated embryonic cells and tumor cells is evident, and thus these assays serve as a model for possible cancer therapeutics. In addition, methods for identifying additional cellular components that interact p53 or p53-related pathways are provided.Type: GrantFiled: July 1, 1998Date of Patent: November 12, 2002Assignee: Board of Regents, The University of Texas SystemInventors: Peter D. Vize, John B. Wallingford
-
Publication number: 20020104109Abstract: The present invention provides improved methods and compositions for the generation of transgenic non-human animals. The present invention permits the introduction of exogenous nucleic acid sequences into the genome of unfertilized eggs (e.g., pre-maturation oocytes and pre-fertilization oocytes) by microinjection of infectious retrovirus into the perivitelline space of the egg. The methods of the present invention provide an increased efficiency of production of transgenic animals with a reduced rate of generating animals which are mosaic for the presence of the transgene.Type: ApplicationFiled: May 4, 2001Publication date: August 1, 2002Inventors: Robert D. Bremel, Gregory T. Bleck
-
Patent number: 6395961Abstract: A method of altering the phenotype of a bird comprises introducing a DNA molecule into the muscle tissue of a bird contained within an egg during in ovo incubation. The DNA molecule is selected to be effective to cause a change in phenotype, such as an increase in growth rate, feed efficiency, immune response, or a combination of these and other phenotypes in the bird after hatch. A DNA molecule may further be selected to increase disease resistance, induce disease prevention, or neutralize maternal antibodies by the expression of an antigen over a period of time.Type: GrantFiled: June 12, 1998Date of Patent: May 28, 2002Assignee: North Carolina State UniversityInventors: James M. Petitte, Catherine A. Ricks, Patricia V. Phelps, Christopher Williams
-
Publication number: 20020013952Abstract: Transgenic non-human animals are described comprising a transgene for a species-specific pathogen and transgene(s) for at least one receptor restricting infection of the pathogen to the host species. Also described is a method for creating the transgenic non-human animal of this invention and a method for screening an agent for the ability to inhibit infection by a species-specific virus using said transgenic non-human animal. The transgenic animal of this invention has a sustained productive viral infection and does not develop a virus-specific immune response, thereby resulting in an extremely useful self-contained system to investigate the factors modulating in vivo replication of human pathogens, the pathophysiological effect of pathogen replication and production, and the effectiveness of novel therapies and vaccines modifying or inhibiting the course of pathogenesis.Type: ApplicationFiled: December 14, 1999Publication date: January 31, 2002Inventors: Harris Goldstein, Jessie B. Paul
-
Patent number: 6291740Abstract: The present invention provides improved methods and compositions for the generation of transgenic non-human animals. The present invention permits the introduction of exogenous nucleic acid sequences into the genome of unfertilized eggs (e.g., pre-maturation oocytes and pre-fertilization oocytes) by microinjection of infectious retrovirus into the perivitelline space of the egg. The methods of the present invention provide an increased efficiency of production of transgenic animals with a reduced rate of generating animals which are mosaic for the presence of the transgene.Type: GrantFiled: June 10, 1999Date of Patent: September 18, 2001Assignee: Wisconsin Alumni Research FoundationInventors: Robert D. Bremel, Anthony W. S. Chan, Jane C. Burns
-
Patent number: 6287863Abstract: Improved recombinant retrotransposon vectors for gene transfer are disclosed. The synthetic vectors are truncated so as to reduce or altogether eliminate homologous recombination with retroviral helper sequences found in helper cells used to propagate the vectors, making them safer for use in humans and providing more space for therapeutic genes. The vectors transmit foreign DNA efficiently, are stable, enable abundant RNA expression from the retrotransposon transcriptional promoter, and through their diversity permit many useful applications in therapeutics and transgenics. Methods are described for rescuing tissue-specifics promoters obtaining expression in primary cells, mapping the genome and other techniques of therapeutic and transgenic utility.Type: GrantFiled: November 9, 1995Date of Patent: September 11, 2001Assignee: Nature Technology CorporationInventor: Clague P. Hodgson
-
Patent number: 6100444Abstract: The non-coding regulatory sequences of the prostate specific antigen (PSA) are described. Non-human transgenic animals are also provided which express human PSA, which is non-naturally occurring in non-human animals.Type: GrantFiled: February 11, 1997Date of Patent: August 8, 2000Assignee: University of Rochester Medical CenterInventors: John G. Frelinger, Richard K. Barth, Chungwen Wei
-
Patent number: 6080912Abstract: The present invention provides improved methods and compositions for the generation of transgenic non-human animals. The present invention permits the introduction of exogenous nucleic acid sequences into the genome of unfertilized eggs (e.g., pre-maturation oocytes and pre-fertilization oocytes) by microinjection of infectious retrovirus into the perivitelline space of the egg. The methods of the present invention provide an increased efficiency of production of transgenic animals with a reduced rate of generating animals which are mosaic for the presence of the transgene.Type: GrantFiled: March 20, 1997Date of Patent: June 27, 2000Assignee: Wisconsin Alumni Research FoundationInventors: Robert D. Bremel, Anthony W. S. Chan, Jane C. Burns
-
Patent number: 6028244Abstract: The invention provides a nonhuman transgenic animal having a transgene disrupting or interfering with expression of G.alpha..sub.q chromosomally integrated into the germ cells of the animal. Cells and cell lines derived from these nonhuman transgenic animals; a method for producing a transgenic nonhuman animal having a phenotype characterized by expression of a transgene which is otherwise not naturally occurring, where the expression of the transgene disrupts or interferes with G.alpha..sub.q activity; a method for determining an effect of an agent on G.alpha..sub.q expression, by administering an effective amount of the agent to a transgenic nonhuman animal having a transgene disrupting or interfering with G.alpha..sub.q, and measuring a physiological response of the transgenic nonhuman animal to the agent, and comparing the physiological response of the transgenic nonhuman animal having a transgene disrupting or interfering with G.alpha..sub.q to a control animal is also provided.Type: GrantFiled: June 11, 1998Date of Patent: February 22, 2000Assignee: California Institute of TechnologyInventors: Stefan Offermanns, Christopher F. Toombs
-
Patent number: 6025540Abstract: The present invention relates to a transgenic non-human mammal comprising a DNA sequence encoding human extracellular superoxide dismutase (human EC-SOD) or a variant thereof which is expressed in the milk. Transgenic mice containing a chimeric whey acidic protein gene promoter operatively linked to human EC-SOD gene were produced. Levels of up to 0.7 mg human EC-SOD protein/mL milk were observed. The mammalian expression system is preferably expressed in a non-human mammal selected from the group containing rabbits, mice, rats, goats, sheep, pigs, llama, camels and bovine species. The human EC-SOD proteins dismutate superoxide radicals and bind heparin. Within the scope of the invention are also method for producing a transgenic non-human mammal capable of expressing human EC-SOD as defined above, and methods of making milk and methods of isolating protein from the milk.Type: GrantFiled: December 7, 1995Date of Patent: February 15, 2000Inventor: Lennart Hansson
-
Patent number: 5969211Abstract: A method for introducing foreign nucleic acid sequences into marine mollusks. A pantropic retroviral vector containing a foreign gene sequence is introduced into fertilized mollusk embryos by electroporation. The gene sequence becomes integrated into the host DNA and encodes a functional protein product. This method has implications in the introduction of disease-resistance and growth-accelerating genes into mollusks.Type: GrantFiled: April 18, 1997Date of Patent: October 19, 1999Assignees: Ther Regents of The University of California, The University of ConneticutInventors: Jane C. Burns, Thomas T. Chen
-
Patent number: 5907080Abstract: The invention features a method which includes the following steps: (a) introducing a transgene into a zygote of a dwarf goat, (b) transplanting the zygote into a pseudopregnant non-dwarf goat, and (c) allowing the zygote to develop to term. In another aspect the invention features a method which includes the following steps: (a) introducing a transgene into an embryo of a dwarf goat, (b) transplanting the embryo into a pseudopregnant non-dwarf goat, and (c) allowing the embryo to develop to term.Type: GrantFiled: November 30, 1995Date of Patent: May 25, 1999Assignee: Nexia Biotechnologies, Inc.Inventors: Costas Karatzas, Carol Keefer, Jeffrey D. Turner